Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACT
U2AF1 mutations occur in up to 11% of myelodysplastic syndrome (MDS) patients. To study the effects of the most common U2AF1 mutation, U2AF1(S34F), on hematopoiesis and pre-mRNA splicing in vivo, we created doxycycline-inducible U2AF1(WT) and U2AF1(S34F) transgenic mice. Following transgene induction, U2AF1(S34F) mice have reduced WBCs, increased hematopoietic stem/progenitor cells, and increased HSC cell cycling compared to U2AF1(WT) mice. U2AF1(S34F) stem cells are at a competitive disadvantage compared to control cells, suggesting that the increase in HSC cell cycling following U2AF1(S34F) expression may lead to stem cell exhaustion. Next, we compared RNA splicing in progenitor cells from U2AF1(S34F) and U2AF1(WT) mice using whole transcriptome RNA-seq. We identified 460 splicing junctions that were differentially expressed in U2AF1(S34F) samples compared to U2AF1(WT). We validated several homologous dysregulated junctions (i.e., across species) in MDS patient bone marrow samples that have mutant U2AF1(S34F) versus U2AF1(WT). Together, these results suggest that mutant U2AF1 expression contributes to the altered hematopoiesis and pre-mRNA splicing observed in patients with U2AF1 mutations. This study also identifies changes in gene isoform expression unique to U2AF1 mutations that may have functional significance for MDS pathogenesis, which is being investigated in ongoing studies.
INTRODUCTION:
The goal of this project is to understand the mechanism of disease pathogenesis induced by U2AF1 mutations in myelodysplastic syndromes (MDS). U2AF1 is a key spliceosome protein that binds the AG dinucleotide of the 3' splice acceptor site in pre-mRNA introns during splicing and is mutated in up to 11% of MDS patients, making it one of the most commonly mutated genes in MDS. Overall, mutations in spliceosome genes occur in up to ~50% of patients with MDS, further implicating altered pre-mRNA splicing in disease pathogenesis. We hypothesize that U2AF1 mutations result in altered mRNA splicing in hematopoietic cells, and thereby lead to altered progenitor/stem cell function and ineffective hematopoiesis. In this project, we will test our hypothesis in the following Specific Aims. Specific Aim 1. We will determine whether the U2AF1(S34F) mutation alters hematopoiesis in vivo. We will inducibly express wild-type and S34F mutant (resulting from the most common U2AF1 mutation) human U2AF1 cDNAs in mice and determine the contribution of mutant U2AF1 to MDS pathogenesis by comprehensively evaluating basal hematopoiesis and stem cell function. Specific Aim 2. We will use RNA-Seq to identify alternatively spliced genes in primary hematopoietic progenitor cells harvested from U2AF1(S34F) mutant mice. We will identify alternatively spliced genes induced by U2AF1 mutations by performing transcriptome sequencing (RNA-Seq) using RNA isolated from wild-type and mutant bone marrow progenitors. Candidate genes with alternative splicing will be interrogated in MDS patient samples with and without U2AF1 mutations and tested for their contribution to disease. M yelodysplastic syndromes (MDS) are the most common adult myeloid malignancy with up to 40,000 new cases diagnosed each year in the United States 1, 2 . MDS are a heterogeneous group of clonal haematopoietic stem cell disorders characterized by peripheral blood cytopaenias and progenitor expansion; approximately one-third of patients will transform to a secondary acute myeloid leukaemia (AML) that has a poor prognosis 3 . The only curative therapy is bone marrow transplantation, which is often not an option because of patient comorbidities 3 . New treatment approaches are greatly needed. At least half of all MDS patient bone marrow samples harbour a mutation in one of several spliceosome genes [4] [5] [6] [7] [8] [9] [10] , highlighting a potential genetic vulnerability. In addition, spliceosome gene mutations often occur in the founding clones of MDS tumours, providing an attractive target for elimination of all tumour cells 10, 11 . Spliceosome gene mutations are mutually exclusive of each other in patients 4, [10] [11] [12] , implying either a redundancy in pathogenic function or that a cell cannot tolerate two spliceosome perturbations at once. With this in mind, we hypothesized that cells harbouring a spliceosome gene mutation would have increased sensitivity to further perturbation of the spliceosome by splicing modulator drugs. To examine this, we utilized sudemycin compounds that bind the SF3B1 spliceosome protein and modulate pre-mRNA splicing [13] [14] [15] . We used sudemycin D1 and D6, which are synthetic compounds that have been optimized by several rounds of medicinal chemistry for their potent in vivo antitumour activity 13 . We examined the sensitivity of spliceosome mutant cells to sudemycin treatment, focusing on mutations in the spliceosome gene U2AF1, which have been identified in 11% of MDS patients, utilizing the S34F missense mutation most commonly found in our studies 4, 5 . Mutant U2AF1(S34F) expression has been shown by our group and others to cause altered pre-mRNA splicing in a variety of cell types, as well as altered haematopoiesis and pre-mRNA splicing in mice 4, 5, [16] [17] [18] [19] .
In this manuscript, we provide evidence that U2AF1(S34F)-expressing cells are sensitive to the splicing modulator drug sudemycin. Haematopoietic cells expressing mutant U2AF1 show reduced survival and altered cell cycle in response to sudemycin D6 in vitro. In vivo treatment of U2AF1(S34F) transgenic mice with sudemycin results in an attenuation of mutant U2AF1-induced haematopoietic progenitor cell expansion that is associated with increased cell death. In addition, unsupervised analysis of whole-transcriptome sequencing (RNA-seq) finds that sudemycin D6 perturbs RNA splicing in both mutant U2AF1(S34F)-and U2AF1(WT)-expressing bone marrow cells; however, sudemycin D6 treatment further modulates mutant U2AF1(S34F)-induced splicing changes to create cumulative effects on cells in vivo. The cumulative RNA-splicing effects of sudemycin and mutant U2AF1 may contribute to the downstream phenotypic consequences we observe in vivo.
Results
Sudemycin alters RNA splicing in primary human CD34 þ cells. We first examined the pre-mRNA splicing alterations induced by sudemycin D6 in primary human haematopoietic cells. We treated CD34 þ haematopoietic progenitor cells isolated from human umbilical cord blood with 1,000 nM of sudemycin D6 or dimethylsulphoxide (DMSO) vehicle control for 6 h in vitro and performed whole-transcriptome (RNA-seq) analysis (n ¼ 6 each, Supplementary Fig. 1 ). We identified robustly altered gene expression and pre-mRNA splicing patterns induced by sudemycin, as shown by unsupervised clustering of samples using expressed genes (Fig. 1a) and pre-mRNA splice junctions (Fig. 1b) , respectively. Our analysis identified 1,030 differentially expressed genes (FDRo5%, |log 2 FC|41) and 18,833 dysregulated splicing events (FDRo5%, |delta per cent spliced in or PSI (DC)|410%, Supplementary Data 1 and 2, respectively) that discriminated between sudemycin D6-treated samples and controls. Sudemycin D6 treatment induced altered pre-mRNA splicing with a bias towards increased exon skipping and intron retention (Fig. 1b) . However, there was no apparent bias in the sequence motif surrounding splice acceptor sites of cassette exons that were alternatively spliced (Fig. 1c) , in contrast to previously observed biases in sequences surrounding alternatively spliced junctions induced by expression of mutant spliceosome proteins U2AF1, .
To determine whether particular pathways are enriched for splicing perturbations, we applied GOseq to 6,278 genes with junctions significantly altered by sudemycin D6 treatment (FDRo5%, |log 2 FC|42). While pathway enrichment was minimal (enrichment scores o2), GOseq analysis indicated that pathways involved in pre-mRNA splicing, RNA processing and transport, cell cycle, as well as ATPase and helicase activity were enriched in splice junctions altered by sudemycin D6 treatment (FDRo10%; Supplementary Data 3). Genes with sudemycinaltered expression were enriched in pathways involved in receptor and signal transduction activities (FDRo10%; Supplementary Data 4).
Mutant U2AF1 cells have increased sensitivity to sudemycin.
To examine the effects of sudemycin D6 on haematopoietic cells expressing mutant U2AF1, we generated K562 human erythroleukaemia and OCI-AML3 AML cell lines that have stably integrated doxycycline-inducible, FLAG-tagged U2AF1(S34F) or FLAG-tagged U2AF1(WT) to control for U2AF1 overexpression ( Supplementary Fig. 2a ,b for K562; Fig. 2c,d for OCI-AML3). Mutant U2AF1(S34F)-expressing K562 cells showed reduced survival and lower IC50 (Po0.0001, extra sum-of-squares F-test) relative to uninduced mutant U2AF1(S34F) and U2AF1(WT)-expressing control cells (Fig. 2a) . These effects were also observed in human OCI-AML3 cell lines expressing mutant U2AF1(S34F) compared with U2AF1(WT)-expressing cells and other control cells (Po0.003, extra sum-of-squares F-test; Fig. 2b ). Reduced survival of K562 cells in the presence of sudemycin D6 is associated with an altered cell cycle profile: U2AF1(S34F)-expressing K562 cells had a decrease of cells in the S-phase and an increase of cells in the sub-G0/G1 and G2/M phases (Fig. 2c) . Furthermore, MDS or AML cells with U2AF1(S34F) mutations treated in vitro with sudemycin D1, a sudemycin compound very similar to D6, showed an increased sensitivity to sudemycin (reduced S-phase) relative to control MDS/AML cells without spliceosome gene mutations (Fig. 2d) . In contrast, treatment of MDS/AML patient cells with the chemotherapeutic drug daunorubicin (not predicted to disrupt splicing) showed no specificity for mutant U2AF1(S34F) samples compared with controls ( Supplementary Fig. 2e ). In addition, human CD34 þ cells expressing U2AF1(S34F) showed increased sensitivity to another splicing modulator drug (E7107) similar to sudemycin ( Supplementary Fig. 2f ).
Sudemycin reduces mutant U2AF1 progenitor expansion in vivo. We next examined the effect of sudemycin treatment in vivo on mutant U2AF1(S34F)-induced phenotypes using our previously described U2AF1(S34F) transgenic mouse model 19 . We induced U2AF1(S34F) or U2AF1(WT) transgenes for 7 days in the bone marrow cells of transplanted mice (to study haematopoietic cell-intrinsic effects) and treated mice concurrently with sudemycin D6 (50 mg kg À 1 per day) or vehicle for 5 of those days; see schema (Fig. 3a) . Sudemycin D6 treatment of transplanted mice showed an attenuation of the previously described 19 mutant U2AF1(S34F)-induced haematopoietic progenitor cell expansion by colony-forming unit (CFU-C) assay (Fig. 3b) and by flow cytometry for lineage-, c-Kit þ , Sca1 þ (KLS) cells (Fig. 3c ) when compared with control U2AF1 mutant mice treated with vehicle and mice transplanted with U2AF1(WT)-expressing bone marrow. The attenuation of mutant U2AF1-induced progenitor expansion by sudemycintreated mice is associated with increased Annexin V þ staining of KLS cells (Fig. 3d ).
Sudemycin and U2AF1 (S34F) splicing effects can be cumulative. To investigate the potential genotype-specific effects of sudemycin treatment on splice isoform expression, we performed whole-transcriptome sequencing (RNA-seq) on U2AF1(S34F)-and U2AF1(WT)-recipient mouse bulk bone marrow cells following in vivo U2AF1 transgene induction and treatment with sudemycin D6 (50 mg kg À 1 per day for 5 days) or vehicle ( Supplementary  Fig. 3a,b) . RNA was harvested 18 h after the last drug treatment (similar to described above; schema shown in Fig. 3a) . Sudemycin D6 treatment at this dose and schedule does not markedly skew the mature lineage distribution within bulk bone marrow of mutant or wild-type (WT) U2AF1 transgenic mice ( Supplementary Fig. 3c ). Using an unsupervised approach, we observed that sudemycin D6 perturbs splicing in both mutant U2AF1(S34F) and U2AF1(WT)-expressing bone marrow cells ; this is visualized by the segregation of samples according to genotype and treatment within a principal component analysis (PCA) of cassette exon (Fig. 4a ) and retained intron ( Supplementary  Fig. 4a ) splicing events. Furthermore, the splicing bias observed in human cells treated with sudemycin (described above) is recapitulated in U2AF1(WT) mouse cells: sudemycin D6 induces exon skipping more often than exon inclusion relative to vehicle (388 of 657 significant (FDRo10%, |DC|41%) events; Po2 Â 10 À 6 , one-sided binomial test), as well as intron retention more often than removal (98 of 145 significant (FDRo10%, Figure 1 | Sudemycin D6 alters gene expression and pre-mRNA splicing in primary human CD34 þ haematopoietic cells. Whole-transcriptome (that is, RNA-seq) analysis was performed on CD34 þ cells isolated from human umbilical cord blood following treatment of samples with 1,000 nM Sudemycin D6 or DMSO vehicle for 6 h (n ¼ 6). Unsupervised hierarchical clustering of (a) expressed genes and (b) splice junctions. Skipped exons (SE, green) and retained introns (RI, purple) event types are visualized. Values are z-scores computed from regularized logarithm values for genes and from per cent spliced in (PSI or C) values for splicing events. (c) Intronic sequence contexts of cassette exon 3 0 splice sites skipped more often in sudemycin-relative to vehicle-treated cells (FDRo5%, |DC|410%, left panel) or skipped more often in vehicle-relative to sudemycin-treated cells (FDRo5%, |DC|410%, middle panel), along with a context of unperturbed control exons (FDR450%, |DC|o0.1%, right panel). Position is relative to the first base in the exon. |DC|41%) events; Po1.4 Â 10 À 5 , one-sided binomial test). As in human CD34 þ cells, the sudemycin-induced changes were not associated with an apparent sequence motif ( Supplementary Fig. 4b) ; however, we did observe the previously reported increase in a T in the À 3 position of the intronic 3 0 splice acceptor site of exons more commonly skipped in mutant U2AF1(S34F) cells [16] [17] [18] [19] (Supplementary Fig. 4c ). In addition, we defined 'high-confidence' sets of U2AF1(S34F) and sudemycin targets, and subsets of those had a high validation rate in orthogonal experimental (NanoString 26 ) and statistical (edgeR 27 ) platforms (Supplementary Information and Supplementary Data 10 and 11) .
Next, we examined potential interactions between the drug and mutation within cells, focusing on exon skipping events. Along these lines, we observed that the exon skipping effects induced by sudemycin D6 (relative to vehicle) within U2AF1(WT)-expressing cells are highly correlated with the drug effects in U2AF1(S34F)-expressing cells (R 2 ¼ 0.8, Po2.2 Â 10 À 16 , F-test, events significant in both comparisons (FDRo10%), Fig. 4b ). The vast majority of these events are concordant (in the same direction of induced change with similar magnitude) across genotypes (slope of the regression line ¼ 0.75), suggesting that sudemycin treatment results in similar splicing alterations in these targets in both mutant U2AF1 and WT cells (Fig. 4b) . We further assessed drug/genotype interaction using a statistical linear model: of 32,529 dysregulated splicing events (across all event types), only 136 showed statistically significant evidence of interaction (that is, synergy or antagonism; DEXSeq, FDRo10%). However, when sudemycin D6 and mutant U2AF1(S34F) dysregulate a junction in the same direction (for example, both increasing exon skipping), this results in a cumulative effect in a sudemycintreated mutant cell that is greater than the effect induced by sudemycin treatment of WT cells (indicated by red and blue colour in Fig. 4b-d) . As an example, U2AF1(S34F) expression induces increased exon skipping in a 4932438A13Rik splice junction compared with U2AF1(WT) in vehicle-treated cells (DC ¼ 0.205, middle two columns in Fig. 4c ). Sudemycin D6 also increases exon skipping of the same junction in U2AF1(WT) (DC ¼ 0.188) and U2AF1(S34F) (DC ¼ 0.204) cells (that is, sudemycin-induced exon skipping is independent of genotype; Fig. 4c ). Therefore, as expected, the cumulative effect induced by both mutation and drug treatment (DC ¼ 0.409) exceeds the individual effects of mutant U2AF1 expression or sudemycin treatment alone, ultimately resulting in different levels of exon skipping in sudemycin-treated cells expressing mutant U2AF1 versus WT cells (Fig. 4c) . The cumulative effect of mutation and drug can also be observed in splicing events that result in increased exon inclusion (Fig. 4d) . Together, these data signify that the effects of sudemycin and U2AF1(S34F) on splicing in the same cell can be cumulativethat is, greater than the separate effects of drug or mutant. 
Dashed line indicates similar effects in U2AF1(WT) and U2AF1(S34F) cells DC Sudemycin induces gene expression alterations. Sudemycin treatment in vivo also results in altered gene expression in mutant U2AF1 mouse bone marrow cells compared with U2AF1(WT)-expressing control cells (Supplementary Data 12) . As with splicing alterations, mouse bone marrow samples segregate by genotype and by treatment in an unsupervised analysis of gene expression (Fig. 4e) . As seen at the junction level, there is a high-degree of correlation between sudemycininduced, gene-level effects (direction and magnitude relative to vehicle) across mutant and WT genotypes (R 2 ¼ 0.8, Po2.2 Â 10 À 6 , F-test, events significant (FDRo10%) in both comparisons, Fig. 4f ). We also observed cumulative effects of mutation and drug on gene expression (colour in Fig. 4f ), which may result in downstream cellular pathway changes. Using GOseq, we identified pathways that were most enriched for differentially expressed genes in mutant cells treated with sudemycin D6 relative to the other genotype and treatment groups (FDRo10%). We found mutant cells treated with sudemycin D6 were enriched in biologic pathways related to immune and inflammatory responses, antigen processing and presentation, cytokine production, leukocyte differentiation, cell death and apoptotic processes, when compared with the other genotype and treatment groups (Supplementary Data 13).
Discussion
We provide evidence suggesting that U2AF1(S34F)-expressing cells are sensitive to the splicing modulator drug sudemycin. Haematopoietic cells expressing mutant U2AF1 have reduced survival and cell cycle changes following sudemycin D6 treatment in vitro. In vivo, sudemycin D6 is capable of attenuating mutant U2AF1-associated expansion of haematopoietic progenitors in transgenic mice that is associated with increased cell death. In addition, while the effects of sudemycin D6 treatment on splicing and gene expression can be independent of the effects of mutant U2AF1 expression, sudemycin D6 treatment can also modulate splicing changes induced by mutant U2AF1(S34F) to create cumulative effects on cells in vivo. Together, these data indicate that mutant U2AF1(S34F)-expressing cells may have a therapeutic vulnerability to splicing modulator drugs such as sudemycin.
Previous studies using splicing modulator drugs, as well as non-pharmacological methods to target splicing factors, have indicated that the spliceosome is a promising therapeutic target for many cancer cell types 13, 14, [28] [29] [30] [31] . Recent studies have suggested that cancers with spliceosome gene mutations may have an increased sensitivity to splicing modulator drugs like sudemycin; 32-34 this study provides further evidence to support this hypothesis. Specifically, we show that mutant U2AF1 cells are sensitive to in vivo treatment with sudemycin. Using unbiased RNA-seq, we show that sudemycin D6 has effects on mutant U2AF1-associated splicing changes, resulting in different levels of transcript isoforms in cells expressing mutant U2AF1 compared with WT following sudemycin treatment. Ultimately, cumulative changes in isoform expression could be the cause of the mutant U2AF1-specific responses to sudemycin treatment that we observe in vitro and in vivo. Identification of critical downstream targets of sudemycin in vivo will likely require examination of various cellular populations within the bone marrow (including haematopoietic stem and progenitor cells) and harvesting cells at more immediate time points following drug treatment-both limitations of the current study. Future studies will focus on generating mutant U2AF1-expressing leukaemias in mice to test the efficacy of sudemycin on fully transformed haematopoietic tumours, as has recently been reported using E7107 to treat Srsf2(P95H)-expressing leukaemias 33 .
Our data and others highlight several possible mechanisms for the sensitivity of spliceosome mutant samples to splicing modulator therapy. Pathway analysis of differentially expressed genes induced by sudemycin revealed enrichment in inflammatory signalling pathways. This is consistent with the enrichment in biological pathways related to cytokine and immune signalling observed following in vivo treatment of Srsf2(P95H) mutant mice with the splicing modulator E7107 (ref. 33), raising the possibility that spliceosome mutant-specific phenotypes observed in mice following splicing modulator drug treatment may be driven by an altered inflammatory response in mutant cells. Whether the altered inflammatory response in mutant cells treated with splicing modulator drugs is a direct result of mutantaltered splicing or gene expression could be explored in future studies. Alternatively, it is also possible that the cumulative effect of sudemycin and mutant U2AF1 expression on pre-mRNA splicing may simply create a state of 'spliceosome sickness' in cells by exceeding a tolerable threshold of splicing perturbations and their downstream consequences. Along these lines, other splicing modulator drugs have been shown to cause increased intron retention, R loop formation, DNA damage and cell death 28, 29, 31, 35 . Spliceosome gene mutations and splicing modulator drugs may both induce these consequences in a cell, and the cumulative effect of the drug and mutation may create a toxic intracellular milieu.
Exploring the clinical utility of splicing modulator therapies in MDS patients with spliceosome mutations who have failed current therapies is warranted and currently being pursued (NCT02841540), as these patients have few treatment options. Whether excessive toxicity will occur in WT cells treated with newer splicing modulators is a major question. Initial phase I clinical trial studies using a splicing modulator, E7107, showed toxicities in some patients with solid tumours, including ocular toxicity (NCT00459823, NCT00499499). The mechanism for the toxicity is not known. Moving forward, mutant U2AF1 and other preclinical models of spliceosome mutations will be valuable in further testing the in vivo efficacy and toxicity of drugs that modulate splicing through various mechanisms. Collectively, our data suggest that a mutant splicing factor together with a splicing modulator drug like sudemycin may create a unique cellular toxicity that could be exploited for therapeutic purposes.
Methods
Isolation and drug treatment of CD34 þ haematopoietic cells. Mononuclear cells from human umbilical cord blood were separated by Ficoll gradient centrifugation (each n value is a pooled set of four individual umbilical cord blood samples). CD34 þ cells were enriched using autoMACS-positive selection (CD34 MicroBead Kit, Miltenyi Biotec) according to the manufacturer's instructions to achieve 490% purity of CD34 þ cells. Following isolation, CD34 þ cells were cultured in X-Vivo media (Lonza) with cytokines (SCF, FLT3L, IL3 and TPO) overnight. For wholetranscriptome sequencing with sudemycin, either sudemycin D6 (1,000 nM) or the vehicle DMSO was added to cells for 6 h, and cells were then harvested for RNA. Tissue acquisition was performed per protocol approved by the Washington University School of Medicine Institutional Review Board.
RNA-seq of CD34 þ cells treated with sudemycin. RNA was isolated from human CD34 þ cells using the miRNEasy Kit (Qiagen), and removal of genomic DNA was performed via a Turbo DNA-Free Kit (Ambion). Ribosomal RNA was removed using Ribozero (Epicenter), followed by cDNA preparation and generation of stranded libraries using the TruSeq Stranded Total RNA Sample Prep Kit (Illumina). Sequencing was performed on the HiSeq2500 platform (Illumina) to generate 2 Â 125 bp paired-end reads. RNA-seq data were deposited in NCBI dbGAP (phs000159.v9).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14060 ARTICLE RNA-seq analysis of human CD34 þ cells treated with sudemycin. Analysis of (stranded) RNA-seq data generated from primary human CD34 þ haematopoietic cells treated with sudemycin D6 was performed using the genome modelling system 36 . Reads were aligned to the human genome (hg19/NCBI build 37) using TopHat 37 version 2.0.8, with annotations provided by Ensembl 38 version 67. All downstream bioinformatic and statistical analyses, including calculation of P values using Fisher's exact test and simulation, were performed in R 39 and python. The heatmap of gene expression was created using normalized expression values output by DESeq2 package (version 1.6.3 (ref. 40) ) that was subsequently z-scored. DESeq2 was used to detect differentially expressed genes, and gene-set enrichment analysis was then performed by applying GOseq 41 (version 1.18.0) to differentially expressed genes (FDRo5%, |log 2 FC|41, DESeq2). Additional details of RNA-seq analysis of gene expression are further described in the Supplementary Methods.
Alternative splicing events were computed via rMATS 42 (version 3.0.8). We generated the heatmap of splice junctions using 'per cent spliced in' (PSI or C) values for exon skipping and intron retention events. For downstream analyses, namely reported dysregulated events and visualization of sequence contexts below, P values for events passing the filter were re-adjusted for multiple hypothesis testing using the method of Benjamini and Hochberg 43 . A positive DPSI value indicates an event that was spliced in more often in the vehicle-treated relative to the sudemycin-treated samples. Sequence contexts of splice sites in exon skipping and intron retention events were visualized using seqLogo version 1.32.1. Dysregulated events visualized were those with |DPSI|410% and having a post-filtering re-adjusted FDRo5% from rMATS. Dysregulated splicing junctions were determined by DEXSeq 4 version 1.12.2. Only expressed junctions were analysed, and gene-set enrichment analysis was performed by applying GOseq to dysregulated junctions (FDRo5%, |log 2 FC|41, DEXSeq). All of these are described in more detail in the Supplementary Methods.
Creation of inducible U2AF1(S34F) and U2AF1(WT) cell lines. Doxycyclineinducible FLAG-tagged WT U2AF1 or FLAG-tagged mutant U2AF1(S34F) lentiviral expression plasmids were previously described 4 , and lentivirus was generated in 293T cells with the packaging plasmids pMD-G, pMD-Lg and REV. Concentrated virus (multiplicity of infection (MOI) of 3 for K562, MOI of 5 for OCI-AML3) was used to transduce K562 cells (ATCC, CCL243) or OCI-AML3 (DSMZ, ACC 582). Transduced cells (marked by green fluorescent protein) were isolated by flow cytometry cell sorting. Expression of mutant or WT U2AF1 was induced using the indicated concentrations of doxycycline hyclate (Sigma, St Louis, MO) in water.
Cell line counting and BrdU incorporation assays. K562 (or OCI-AML3) cells in culture were seeded at B200,000 cells per ml with different concentrations of Sudemycin D6 (or with DMSO control) following 48 h of initial doxycycline treatment to induce mutant U2AF1(S34F) or U2AF1(WT) expression. Cells were counted on Days 0, 3 and 5 of drug treatment using flow cytometry counting particles (Spherotech) as per the manufacturer's recommendations, along with propidium iodide (Millipore) to exclude dead cells from counts. Day 5 data were graphed in Graphpad Prism (Graphpad Software Inc.) using a nonlinear regression best fit line of the log (drug) versus response for each genotype and treatment. Statistical differences between curves were examined by the extra sum-of-squares F-test function in Graphpad Prism. For K562 cells, 5-bromodeoxyuridine (BrdU) incorporation was performed using the BrdU Flow Kit (APC, #559619, BD Biosciences) as per the manufacturer's instructions using a 45 min pulse of BrdU of cells in culture on Day 5 of drug treatment.
Culture of MDS/AML cells and EdU incorporation assay. Primary MDS and AML cells were cultured on irradiated (4,000 cGy) HS27 stroma as described previously 45 . Briefly, MDS or AML cells were cultured on stroma for 2-3 days and then treated with increasing doses of sudemycin D1 (or daunorubicin in Supplementary Information). MDS and AML cells were cultured with drug for 3 days and analysed for cell proliferation by EdU incorporation assay (Invitrogen) via flow cytometry. All experiments were performed on 96-well plates. Studies were performed per protocol approved by the Washington University School of Medicine Institutional Review Board and with patients' consent for sample use.
Murine bone marrow transplant and drug infusion. To generate mice for each experiment, 1 Â 10 6 transgenic mouse donor bone marrow cells from two to three mice pooled (CD45.2) were transplanted into at least five lethally irradiated (1,100 rads) congenic WT recipient mice (C57BL/6 Â 129S4Sv/Jae)F1 (CD45.1/CD45.2) per genotype, as previously described 19 . Donor mice were between 8 and 12 weeks of age, and recipient mice ranged from 6 to 12 weeks of age; donor and recipient mice were sex-matched (both sexes were used in experiments). Donor chimerism was confirmed Z6 weeks post transplantation to ensure engraftment of transgenic bone marrow. Post-engraftment, intrajugular catheters were surgically placed for intravenous drug infusions of mice over 4 h daily for 5 days with either sudemycin D6 (50 mg kg À 1 ) or vehicle control (HP-b-CD (2-hydroxypropyl)-b-cyclodextrin in phosphate buffer pH 7.4). This dose was determined by prior studies 13 . Mice received doxycycline chow to induce U2AF1(S34F) or U2AF1(WT) transgene on the day of surgery, and drug infusion began 2 days later. Mice of each group were randomly selected for treatment with sudemycin or vehicle control. Investigators were not blinded to the group allocation during the experiment or analysis. Animals were excluded from analysis if their catheters did not remain patent during the entire treatment period. Mice were euthanized for analysis the day following the last drug infusion. Sample sizes for experiments were chosen to allow for statistical comparison between groups. All mouse procedures were performed according to the protocols approved by the Washington University Animal Studies Committee.
Mouse haematopoietic progenitor cell assay. Methylcellulose progenitor CFU-C assays were performed using Methocult GF M3434 (Stem Cell Technologies). Bulk bone marrow cells were obtained from experimental mice, and red blood cells were lysed before plating of 10,000 bone marrow cells per 1.3 ml media; each sample was evaluated in duplicate. Progenitor colonies (defined as Z40 cells per colony) were counted following 7 days culture at 37°C with 5% CO 2 .
Mouse haematopoietic cell flow cytometry. For flow cytometry, all antibodies are from eBioscience (unless indicated), and catalogue number provided (if available). For haematopoietic progenitor/stem cells, we used the following antibodies (volume of antibody used in 200 ml of fluorescence-activated cell sorting (FACS) buffer for staining is also indicated): CD45.1-APC (#17-0453, 3 ml), CD45.2-PE (#12-0454, 3 ml), Biotin-conjugated lineage (Gr-1 (#13-5931, 0.25 ml), Cd3e (#13-0032, 0.5 ml), B220 (#13-0452, 0.5 ml), Ter119 (#13-5921, 0.5 ml) and CD41(#13-0411, 1 ml)), streptavidin secondary-eFluor605NC, c-Kit-APCeFluor780 (#47-1172, 1.5 ml), Sca1-PerCP-Cy5.5 (#45-5981, 0.5 ml). Flow cytometry for Annexin V þ staining of KLS cells was performed following initial staining of KLS cells as described above using Annexin V-APC (2.5 ml, BD Biosciences, #550474) incubated in 1 Â Annexin V binding buffer (BD Biosciences). All other incubations occurred in FACS buffer. All flow cytometry analyses were performed using FACScan or Gallios cytometers (BD Biosciences) and analysed using the FlowJo software (FlowJo, LLC, Ashland, OR, USA).
RNA-seq of mouse bone marrow cells in vivo. RNA was isolated and prepared as described above for human cells, using the miRNEasy Kit (Qiagen) followed by removal of genomic DNA via a Turbo DNA-Free Kit (Ambion) and ribosomal RNA using Ribozero (Epicenter). The cDNA preparation and generation of stranded libraries was performed using the TruSeq Stranded Total RNA Sample Prep Kit (Illumina). Sequencing was performed on the HiSeq2500 platform (Illumina) to generate 2 Â 126 bp paired-end reads. The RNA-seq data have been deposited in NCBI's Gene Expression Omnibus 46 and are accessible through the GEO Series accession number GSE89834.
RNA-seq analysis of mouse bone marrow cells in vivo. Analysis of (stranded) RNA-seq data generated from U2AF1(S34F) and U2AF1(WT) murine cells treated with sudemycin D6 or vehicle was performed similarly to the human CD34 þ cell analysis described above, with some differences as follows. Alignment again utilized genome model system, and reads were aligned to the mouse genome (mm9/NCBI build 37). 'Per cent spliced in' (PSI or C) values were calculated for all four conditions ({U2AF1(S34F), U2AF1(WT)} Â {sudemycin D6, vehicle}) using rMATS. PCA was performed independently on events annotated by rMATS as skipping cassette exons or retaining introns using the z-scored C values of these events.
To quantitate the simultaneous effect of treatment and genotype for each splicing event, we calculated the change in per cent spliced in values for the four pairwise comparisons in which the genotype (alternately, treatment) was the same in the pair, but in which the treatment (alternately, genotype) differed. We refer to the unchanged condition as the 'context' and to the two conditions that differ as 'A' and 'B' and denote the corresponding change in the per cent spliced in values as DC context A À B ¼ C context;A À C context;B . In addition, we defined the cumulative effect in a mutant, drug-treated cell relative to a WT, vehicle-treated cell as DC cum ¼ C Sud;MT À C Veh;WT . Each of the five comparisons described were evaluated using rMATS, and P values for these events were then adjusted for multiple hypothesis testing as described above. Scatterplots were then plotted of cassette exon-skipping events dysregulated by sudemycin in both U2AF1(WT) and U2AF1 (S34F) Non-additive (that is, super-additive synergistic or sub-additive antagonistic) interactions between drug and mutation were assessed in DEXSeq by comparing a generalized linear model that included main effects for drug and mutation with a second model that additionally included an interaction term representing drug/mutation synergy or antagonism.
As At the gene-level, PCA was performed as described above for human expressed genes. Genes differentially expressed within the above-described five conditions were determined via DESeq2. Scatterplots were then made comparing log 2 fold changes of genes dysregulated by sudemycin in both U2AF1(WT) and U2AF1(S34F) contexts (FDRo10% in both comparisons). Pathways enriched (FDRo10%) for genes differentially expressed between U2AF1(S34F), sudemycin-treated cells and U2AF1(WT) and/or vehicle-treated cells were independently determined in a pairwise manner using GOseq. Again, expanded details of this approach can be found in the Supplementary Methods.
Data availability. All relevant data generated in this study are available at data-deposition sites. For human CD34 þ cells treated with sudemycin D6 in vitro, data are available at NCBI dbGAP (phs000159.v9). For transgenic mice expressing mutant U2AF1(S34F) or U2AF1(WT) and treated with sudemycin D6 in vivo, data are available at Gene Expression Omnibus (GSE89834). pre-mRNA binding and splicing. Leukemia 29, 909-917 (2014 13, 1033-1045 (2015 . MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by peripheral blood cytopenias, with up to 30% of patients experiencing progression to secondary acute myeloid leukemia (AML) . Mutations in spliceosome genes have been identified in over half of MDS patient bone marrow samples, making it the most common class of genes mutated in MDS Graubert et al., 2012; Papaemmanuil et al., 2011; Thol et al., 2012; Visconte et al., 2012; Walter et al., 2013; Yoshida et al., 2011) . The recurrentlymutated spliceosome genes encode factors that are involved in the recognition of the 3 0 -intronic splice site and are mutually exclusive of one another in patient samples Papaemmanuil et al., 2013; Walter et al., 2013; Yoshida et al., 2011) , implying that they may contribute similarly to MDS pathogenesis or, alternatively, may not be tolerated by a cell when they co-occur.
Our group and others identified mutations in U2AF1 (U2 small nuclear RNA auxiliary factor 1) in 11% of patients with MDS, making it one of the most commonly mutated genes in this disease (Graubert et al., 2012; Yoshida et al., 2011) . In addition, U2AF1 mutations typically occur in the founding clone, suggesting they may play an important role in disease initiation Papaemmanuil et al., 2013; Walter et al., 
Significance
Mutations in spliceosome genes occur in up to $50% of patients with myelodysplastic syndromes (MDS), suggesting that perturbations in pre-mRNA splicing contribute to disease pathogenesis. We generated a murine model of the most common mutation in the spliceosome gene U2AF1 and observed hematopoietic phenotypes and pre-mRNA splicing alterations that also occur in patients with MDS or acute myeloid leukemia. Concordant changes in isoform expression of RNA processing genes, ribosomal genes, and recurrently mutated genes in myeloid cancers in the mouse and human highlight cellular processes and pathways that may functionally contribute to mutant U2AF1-associated diseases. Determining whether splicing changes in the same genes are induced by other MDS-associated spliceosome gene mutations may further prioritize key target genes in MDS. 2013). U2AF1 mutations have also been identified across major cancer types, including AML, lung adenocarcinoma, head and neck squamous cell carcinoma, uterine corpus endometrial carcinoma, bladder urothelial carcinoma, breast adenocarcinoma, and colorectal carcinoma, further implicating U2AF1 broadly in cancer pathogenesis . During normal pre-mRNA splicing activity, the U2AF1 protein binds to the AG dinucleotide at the 3 0 end of the intron, thereby assisting its cofactor U2AF2 in recruitment of the U2 snRNP for spliceosome activation as part of the spliceosome E/A complex (Wahl et al., 2009; Wu et al., 1999) .
It is unknown how U2AF1 mutations contribute to MDS pathogenesis. Several groups have reported splicing changes in cells expressing mutant U2AF1, including cell lines (HeLa, K562), primary human CD34 + cells, and patient AML and MDS cells (Brooks et al., 2014; Graubert et al., 2012; Ilagan et al., 2014; Okeyo-Owuor et al., 2014; Przychodzen et al., 2013; Yoshida et al., 2011) . However, the downstream targets of mutant U2AF1 identified in these studies are variable, perhaps due to differences in cell types, co-occurring mutations, and experimental methods used. Initial in vivo studies using a retroviral overexpression model showed that mouse bone marrow cells expressing mutant U2AF1 have reduced repopulation ability . Together, these data lead us to hypothesize that mutant U2AF1-induced splicing alterations and subsequent changes in gene isoform expression result in abnormal hematopoiesis.
RESULTS
Splicing Is Altered in Primary Human AML Cells Expressing Mutant U2AF1
To examine the effects of U2AF1 mutations on global splicing in primary patient samples, we used RNA-seq data from the The Cancer Genome Atlas (TCGA) AML cohort (Cancer Genome Atlas Research Network, 2013). We identified eight samples with a spliceosome gene mutation, including six samples with a U2AF1 mutation affecting the S34 amino acid (four S34F, two S34Y), one sample with U2AF1(Q157P), one sample with SF3B1(K700E), and 102 samples without a mutation or copy number alteration in spliceosome genes (Table S1 ). Unsupervised clustering using the splicing ratio of cassette and mutually exclusive exon splice junctions segregated the six mutant U2AF1(S34) patient samples from the 102 control, the U2AF1(Q157P), and SF3B1(K700E) samples (Figure 1 ), indicating that splicing is distinctly altered in primary patient cells with U2AF1 mutations affecting the S34 amino acid.
Generation of U2AF1(S34F) Transgenic Mice
To study the in vivo consequences of U2AF1 mutations on splicing and hematopoiesis in an isolated genetic system and to prioritize splicing alterations identified in primary patient samples, we created a mouse model to study the most abundant U2AF1 mutation found in MDS patients [U2AF1(S34F)]. Using a previously-validated, single-copy, site-specific integration approach (Beard et al., 2006) , we generated doxycyclineinducible U2AF1(S34F) and control U2AF1(WT) transgenic mice. We integrated human cDNA (human and mouse U2AF1 proteins differ in only one amino acid in the polyglycine tract of the C-terminal RS domain) coding for U2AF1(S34F) or U2AF1(WT) into the Col1a1 locus of KH2 mouse embryonic stem (ES) cells ( Figure S1A ). KH2 ES cells contain the M2rtTA tetracycline-responsive transactivator protein (rtTA) ubiquitously expressed from the Rosa26 locus, which allows for induction of the integrated U2AF1(S34F) or U2AF1(WT) transgene following treatment of cells with the tetracycline derivative doxycycline (Figure 2A ). Integration was validated in both mouse lines by Southern blot analysis ( Figure 2B ). These transgenic mouse lines display dose-dependent, inducible, in vivo expression of the integrated U2AF1 transgene (S34F or WT) in bone marrow cells ( Figure 2C ). For subsequent experiments, we used a doxycycline dose (625 ppm doxycycline chow) that induced levels of exogenous transgene expression similar to endogenous mouse U2af1 levels in bone marrow cells, consistent with the heterozygous expression of U2AF1 mutations in MDS patient bone marrow samples (Graubert et al., 2012) . This dose of doxycycline induced similar levels of transgene expression in U2AF1(S34F)/rtTA and U2AF1(WT)/rtTA double transgenic mice, as determined by pyrosequencing (data not shown). U2AF1(WT) and U2AF1(S34F) expression was in excess of normal mouse U2af1 expression levels, resulting in approximately double the normal protein level in cells ( Figure S1B) ; however, overexpression of human U2AF1 transgene(s) at this dose of doxycycline has no impact on endogenous mouse U2af1 expression ( Figure S1C ). U2AF1 transgene expression was induced in myeloid and lymphoid cell lineages, as well as in stem and progenitor cells ( Figure S1D ). Table S1 .
Hematopoietic Cell Lineage Is Altered in U2AF1(S34F)-Recipient Mice
To examine the cell-autonomous effects of mutant U2AF1(S34F) expression on hematopoiesis, we transplanted transgenic mouse bone marrow into lethally-irradiated wild-type congenic recipient mice, allowing for R6 weeks of engraftment prior to induction of the transgene. Initial experiments were conducted with all six possible genotypes produced from transgenic colonies. Control genotypes of wild-type (nontransgenic) mice, single transgenic rtTA-only, U2AF1(WT)-only, and U2AF1(S34F)-only, and double transgenic U2AF1(WT)/rtTA mice were similar in parameters measured ( Figure S2A ). Given the similarity of all controls, subsequent experiments were performed with the U2AF1(S34F)/rtTA double transgenic mice and two control genotypes: U2AF1(WT)/rtTA double transgenic mice and single transgenic rtTA-only mice (littermates from the U2AF1[S34F] transgenic mouse colony). Examination of hematopoietic compartments in recipient mice following one month of doxycycline to induce transgene expression revealed a reduction in peripheral blood total white blood cell (WBC) counts in U2AF1(S34F)/rtTA-recipient mice compared to U2AF1(WT)/rtTA-and rtTA only-recipient controls (4.3 versus 7.11 and 7.13 K/ml, respectively, p = 0.014) (Figure 3A) , but no difference in red blood cell parameters or platelet counts ( Figure S2B ). This peripheral blood leukopenia was stable and persisted for up to 12 months ( Figure 3A) ; it was also dependent on mutant U2AF1 expression, since the WBC counts in mutant U2AF1(S34F)/rtTA-recipient mice recovered to levels similar to U2AF1(WT)/rtTA-recipient mice after halting doxycycline treatment, even after 6 months of transgene expression ( Figure S2C ). Flow cytometry analysis of mature lineage cells in the peripheral blood revealed a reduction in B cells and monocytes in U2AF1(S34F)/rtTA-recipient mice compared to controls ( Figure 3B ).
There were no differences in bone marrow cellularity or spleen weights in U2AF1(S34F)/rtTA-recipient mice compared to controls ( Figure S2D ). However, mature cell lineage distribution was altered in the bone marrow of U2AF1(S34F)/rtTA-recipient mice after one month of doxycycline. Both monocytes and B cells were reduced in U2AF1(S34F)/rtTA-recipient mouse bone marrow, and neutrophils were increased ( Figure 3C ). The reduction of monocytes in the bone marrow of U2AF1(S34F)/ rtTA-recipient mice occurred as soon as 5 days after transgene induction ( Figure S2E ) and was associated with an increase in Annexin V + and phospho-H2AX staining of monocytes (Figure 3D) . In vitro culture of transgenic mouse bone marrow revealed a similar trend in Annexin V + and phospho-H2AX flow cytometry in U2AF1(S34F)/rtTA-expressing cells compared to controls ( Figure S2F ). There was no evidence of bone marrow dysplasia in U2AF1(S34F)/rtTA-recipient mice ( Figure S2G ). The overall survival of U2AF1(S34F)/rtTA-and U2AF1(WT)/ rtTA-recipient mice was similar ( Figure S2H ), and mutant mice did not develop MDS or AML after at least 1 year of continuous doxycycline.
U2AF1(S34F)-Recipient Mice Have Increased Progenitor Cells in Bone Marrow and Spleen, but Stem Cells Have a Competitive Disadvantage in Repopulation Assays
Following 1 month of doxycycline to induce transgene expression, U2AF1(S34F)/rtTA-recipient mice displayed an increased frequency of myeloid progenitors in both bone marrow ( Figure 4A ) and spleen ( Figure 4B ) by progenitor colony forming assay (CFU-C) compared to U2AF1(WT)/rtTA-and rtTA-only-recipient control mice. This increase was also seen by flow cytometry analysis for c-Kit + /lineage À (KL) cells in the bone marrow ( Figure S3A ), as well as for common myeloid progenitors (CMP) in bone marrow ( Figure 4C ) and spleen ( Figure 4D ) of U2AF1(S34F)/ rtTA-recipient mice compared to controls. Granulocyte/macrophage progenitors (GMP) were variably increased ( Figure S3B ) Col1a1 probe to detect the integration of U2AF1(S34F) or U2AF1(WT) transgenes. Flip-in of the pBS31' vector is detected by the appearance of a 4.1 kb band. Frt is the modified frt locus (6.7 kb) , and WT is the wild-type locus (6.2 kb).
(C) Doxycycline-dose response curve of U2AF1 transgene expression relative to endogenous mouse U2af1 in bone marrow cells measured by RT-PCR followed by pyrosequencing assay (n = 2-7). Data are represented as mean ±SD. The 625 ppm doxycycline chow (*) was used in all subsequent experiments; ppm, parts per million. See also Figure S1 .
and megakaryocyte/erythroid progenitors (MEP) were unchanged in mutant mice compared to controls ( Figure S3C ). Flow cytometry for the stem cell-enriched compartment defined by c-Kit + /lineage -/Sca-1 + (KLS) cells also showed an increase in the bone marrow of U2AF1(S34F)/rtTA-recipient mice compared to controls ( Figure 4E ) following 1 month of doxycycline. Further characterization of stem cells by flow cytometry using SLAM and CD34/Flk2 revealed a trend toward increased multipotent progenitors, but no difference in shortterm and long-term stem cell populations ( Figure S3D ). The increase in bone marrow stem-enriched and progenitor cells (KLS, KL, CMP) measured by flow cytometry and by CFU-C in U2AF1(S34F)/rtTA-recipient mice was detectable following only 5 days of doxycycline exposure (Figures S3E-S3H ). The increased frequency of KLS cells after 5 days of transgene induction was associated with increased Ki67 + staining in KLS cells from U2AF1(S34F)/rtTA-recipient mice compared to controls ( Figure 4F ); a similar trend was seen for BrdU incorporation ( Figure S3I ). There was no increase in hematopoietic stem-enriched and progenitor cells measured by flow cytometry and methylcellulose in the absence of doxycycline in U2AF1(S34F)/ rtTA-recipient mice ( Figures S3E, S3G , and S3H), confirming this early phenotype at 5 days was not due to doxycycline-independent transgene expression. Next, we evaluated stem cell function using a competitive repopulation assay. Although we observed an increase in the frequency of stem-enriched and progenitor cells in mutant U2AF1-recipient mice, competitive repopulation assays revealed a disadvantage for U2AF1(S34F)/rtTA-expressing stem cells compared to U2AF1(WT)/rtTA-expressing cells in primary recipient mice ( Figure 4G ). The competitive disadvantage was sustained when the bone marrow from primary recipients was transplanted into secondary and tertiary recipient mice ( Figure 4H ).
Comprehensive RNA Sequencing of U2AF1(S34F)-Expressing Mouse Bone Marrow Progenitors Reveals Splicing Alterations MDS patient bone marrow samples have an increased fraction of common myeloid progenitors (CMPs) compared to normal bone marrow donors (Pang et al., 2013; Woll et al., 2014) , and we observed an increase in CMPs in mutant U2AF1 mouse bone marrow as early as 5 days following doxycycline exposure with a concomitant increase in CFU-C formation. Therefore, we sorted donor-derived CMPs from U2AF1(S34F)/rtTA-and U2AF1(WT)/ rtTA-recipient mice following 5 days of transgene induction and performed transcriptome sequencing (RNA-seq) to detect U2AF1(S34F)-induced splicing alterations. The levels of transgene induction were similar among samples ( Figure S4A ). On average, CMP samples yielded 3.2 3 10 8 sequencing reads (Figure S4B) , with an average of 2.0 3 10 8 uniquely mapped reads across samples ( Figure S4C ). The distribution of reads from various species of RNA was similar, with mutant samples having a slightly higher percentage of intergenic bases (p < 0.05) and lower percentage of coding bases (p = 0.05) ( Figure S4D ).
Unsupervised clustering based on the splicing ratio of cassette and mutually exclusive exon junctions segregated U2AF1(S34F)-expressing CMP samples from U2AF1(WT) controls ( Figure 5A ), as it did for patients with AML ( Figure 1 ). DESeq (Anders and Huber, 2010) , an algorithm that accounts for RNAseq replicate data and biologic variation, identified changes in overall gene expression in 128 genes (FDR < 0.1) in U2AF1(S34F)/rtTA samples compared to U2AF1(WT)/rtTA controls (Table S2) . Using these genes, we performed gene set enrichment and pathway analyses with GOseq (Young et al., 2010) and identified an enrichment of genes involved in immune response and leukocyte activation processes (FDR < 0.1) (Table S3) .
DEXSeq (Anders et al., 2012) , an algorithm that identifies altered junctions while accounting for changes in overall gene expression, identified 742 splicing junctions that were differentially expressed in 633 genes in U2AF1(S34F)/rtTA samples compared to U2AF1(WT)/rtTA controls (FDR < 0.1) (Table  S4) . Using these 633 genes, we again performed gene set enrichment and pathway analyses and identified an enrichment of genes involved in RNA binding (FDR < 0.1) ( Figure 5B ). The majority of differentially spliced junctions in U2AF1(S34F)/rtTA samples compared to U2AF1(WT)/rtTA controls were classified as cassette exon, simple alternative 3 0 splice acceptor site, and coordinate cassette exon events ( Figure S4E ).
U2AF1(S34F) Has Altered 3
0 Splice Acceptor Sequence Preference To further examine the effects of U2AF1(S34F) expression on splicing in vivo, we determined the consensus sequence flanking the AG dinucleotide at the 3 0 splice acceptor site known to be Results are depicted in Logos plots. ss, splice site. See also Figure S4 and Tables S2, S3 , and S4.
recognized by U2AF1 during splicing (Wu et al., 1999) . In contrast to the sequence motif seen in non-dysregulated control junctions ( Figure 5C ), exons skipped more frequently by mutant U2AF1(S34F) relative to U2AF1(WT) were enriched for uracil (indicated by a T) in the À3 position relative to the AG dinucleotide ( Figure 5D ). We observed a similar pattern in alternative 3 0 splice site usage; there is an enrichment of T in the À3 position of canonical 3 0 splice sites whose alternative 3 0 splice site was used more frequently in mutant U2AF1(S34F)/ rtTA samples relative to U2AF1(WT)/rtTA controls ( Figure 5E ). This pattern is the same as seen in AML patient samples with U2AF1 mutations and in primary human CD34 + cells expressing U2AF1(S34F) or U2AF1(WT), and similar to previously reported data in human samples (Brooks et al., 2014; Ilagan et al., 2014; Okeyo-Owuor et al., 2014; Przychodzen et al., 2013) . These data indicate that the sequence-specific pattern of altered splicing induced by mutant U2AF1 is similar in mouse and human cells.
U2AF1(S34F)-Induced Splicing Changes Are Enriched
in Genes Involved in RNA Processing and Splicing, Protein Translation, and Recurrently Mutated Genes in MDS/AML To prioritize altered splicing events for further analysis, we intersected significant junctions (DEXSeq; FDR < 0.1) across three datasets: mouse CMP samples (n = 219 junctions), AML patient samples with and without U2AF1 mutations (n = 162 junctions), and our previously described primary human CD34 + cells overexpressing U2AF1(S34F) or U2AF1(WT) (n = 1,652 junctions) (Okeyo-Owuor et al., 2014) . The intersection was (necessarily) composed of homologous junctions and was additionally restricted to include only concordantly dysregulated (same direction of log fold change) junctions; 17 homologous dysregulated junctions (p < 0.0001; simulation) were present in 13 genes (Figures 6A and 6B) . Several of the dysregulated junctions corresponded to the same splicing event in a transcript and were (Table 1) , plotted in descending order based on CMP results. U2AF1 was excluded due to an inability to differentiate endogenous versus exogenous U2AF1(WT) transcript in CD34 + cells.
See also Figure S5 and Tables S5 and S6. identified as reciprocal splice junctions. All of these junctions occur in known isoforms, though the function of most of these isoforms remains largely unknown. Several of these junctions occur in genes mutated in MDS and AML (GNAS, PICALM) (Bejar et al., 2011; Borel et al., 2012) or known to be involved in stem cell biology (H2AFY, MED24) (Buschbeck et al., 2009; Chia et al., 2010; Gaspar-Maia et al., 2013) .
To broaden the list of potentially concordant changes across species, we performed a meta-analysis of the three independent datasets using Fisher's combined probability test (Brown, 1975) and identified 555 significantly dysregulated homologous junctions in 415 genes across all three datasets (FDR < 0.1) ( Table S5 ). The larger number of dysregulated junctions relative to the conservative intersection above enables both consensus sequence analysis and pathway/gene-set enrichment analyses. Skipped exons from the Fisher dataset also show an enrichment of T at the À3 position of 3 0 splice sites, as in the CMP data ( Figure S5 ). We hypothesized that splicing in biologic pathway(s) could be widely disrupted by mutation of an upstream splicing factor. To test this, we performed gene set enrichment and pathway analyses on the 415 splicing-dysregulated genes using GOseq. This resulted in 28 pathways/ categories identified as significant (FDR < 0.1, Enrichment > 2) by one of the three independent analyses of KEGG pathways or GO molecular function (MF) or biological processes (BP) categories; 14 of these contain genes involved in RNA processing, RNA splicing, RNA localization/transport, and RNA binding, whereas 11 were involved in protein translation processes and ribosomal pathways (Table S6) . Additionally, spliceosome genes (p = 4.68 3 10 À8 , Table S1 ) and genes recurrently mutated in MDS and AML (Bejar et al., 2011; Cancer Genome Atlas Research Network, 2013; Haferlach et al., 2014; Papaemmanuil et al., 2013; Walter et al., 2013 ) (p = 0.03, Table S7 ) were enriched in the 415 splicing-dysregulated genes (Table 1 and Figure 6C ). Oncogenes and tumor suppressors (Supek et al., 2014) were also highly represented (p = 0.09, data not shown).
U2AF1(S34F)-Induced Splicing Changes Are Present in Human MDS Bone Marrow Samples
Next, we examined MDS patient bone marrow samples for mutant U2AF1-induced splicing changes discovered by RNAseq analysis in a subset of affected genes. Dysregulated splicing events were prioritized for validation by overlap in the three datasets, splicing ratio change, or known biological function of the gene, with particular focus on genes mutated in MDS. Mutant U2AF1-induced splice isoform changes identified by RNA-seq analysis were concordant with RT-PCR of MDS patient bone marrow samples for seven of eight splicing events examined, including H2AFY, BCOR, PICALM, GNAS, KDM6A, KMT2D (MLL2) , and MED24; only EIF4A2 showed no difference ( Figure 7 and data not shown).
DISCUSSION
In this study, we provide evidence that mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in the primary hematopoietic progenitor cells of mice. U2AF1(S34F) expression in mice results in leukopenia and changes in the distribution of mature hematopoietic lineages in the peripheral blood and bone marrow. In addition, U2AF1(S34F) expression increases the frequency of progenitor cells in the bone marrow and spleen of mice as well as the frequency of progenitor cells that are cycling in the bone marrow. We identify U2AF1(S34F)-specific changes in splice isoforms in 633 genes in mouse common myeloid progenitors. Finally, through an integrative meta-analysis of three unique RNA-seq datasets, we identify splice junctions that are consistently altered across species by mutant U2AF1 expression and that are enriched in RNA processing genes, translational processes/ribosomal genes, and recurrently mutated genes in MDS/AML. Collectively, these results suggest that U2AF1(S34F)-induced alternative splicing may contribute to the altered hematopoiesis that is characteristic of patients with MDS.
Mutant U2AF1(S34F) mice display several phenotypes associated with MDS, including leukopenia, increased apoptosis of maturing cells in the bone marrow, and progenitor cell expansion (Catenacci and Schiller, 2005; Hamblin, 1992; Pang et al., 2013 ; 
ZMAT2
Fisher FDR < 0.1. See also Table S7 . Raza et al., 1995a Raza et al., , 1995b Shetty et al., 2000; Woll et al., 2014; Yoshida, 1993 (20) or ASXL1 mutations Damm et al., 2012; Papaemmanuil et al., 2013; Walter et al., 2013 ) (or with other common mutations in MDS, like those in TET2 or DNMT3A), may be necessary to determine whether U2AF1 mutations require a specific genetic context to cause MDS or AML. Ultimately, U2AF1 mutations may contribute to ineffective hematopoiesis that is typical in MDS, whereas other mutations confer clonal dominance. This mouse model could be used to address these questions.
In this study, we show U2AF1(S34F)-induced splicing alterations in primary hematopoietic cells in an isolated genetic system in vivo. By using primary mouse CMPs and human CD34 + cells, we capitalize on identifying early splicing changes that are induced by mutant U2AF1 expression in the absence of transformation. Importantly, expression of mutant U2AF1 in mouse bone marrow cells results in an altered 3 0 splice acceptor site sequence preference that is identical to the pattern observed in human cells, suggesting that the same mechanism of altered splicing is conserved across species and credentialing the mouse model for mechanistic studies.
We identified a list of consistently altered candidate genes that may contribute to myeloid disease pathogenesis. Comparison of these datasets with dysregulated junctions found in lung adenocarcinoma patient samples with U2AF1 mutations suggests that at least some genes with altered splicing are shared across cancer and cell types harboring U2AF1 mutations; indeed, 13 of 29 genes with significant alterations associated with U2AF1 mutations in both lung adenocarcinoma and AML are also present in our list of junctions identified by meta-analysis (Brooks et al., 2014) .
Further studies will be needed to identify the consequences of mutant U2AF1-induced splicing alterations for hematopoiesis and myeloid disease. It is still unknown if the contribution of U2AF1 mutations to MDS pathology involves pre-mRNA splicing alterations of one, a select few, or many genes of interest. Future rescue experiments using target mRNAs/shRNAs to alter isoform expression in mice will be necessary to address this question. However, the observation that dysregulated splicing junctions induced by mutant U2AF1(S34F) are enriched in recurrently mutated genes in MDS/AML raises the possibility that subtle changes in isoform expression in one or more genes may contribute to mutant U2AF1-associated disease. Changes in isoform expression of cancer-associated genes may have important consequences for a cell. For example, different isoforms of NRAS have been shown to activate different signaling molecules, and expression of a rare isoform results in increased cell proliferation and transformation when compared to other NRAS isoforms (Eisfeld et al., 2014) . We identified consistent splicing alterations in several genes commonly affected by loss of function mutations in MDS and cancer, including BCOR and KDM6A; however, splicing changes in both genes resulted in frame-preserving isoforms. Although the functional consequences of these changes are unknown, the dysregulated isoform of BCOR has been shown to lack a domain necessary to interact with the transcription factor AF9 (a common fusion partner of MLL) and repress AF9 transcriptional activity (Srinivasan et al., 2003) .
We report here that perturbations in spliceosome and RNA processing genes occur in three independent mutant U2AF1 RNA-seq datasets. It raises the possibility that mutation of a spliceosome gene may result in autoregulatory changes in splicing machinery by altering isoform expression (Jangi and Sharp, 2014) . This may account for the mutual exclusivity of spliceosome gene mutations in patients with MDS Papaemmanuil et al., 2013; Walter et al., 2013; Yoshida et al., 2011) . Perturbations in the splicing process may have consequences for genome stability, as missplicing has been implicated in co-transcriptional R-loop formation (RNA:DNA hybrid) (Chan et al., 2014; Skourti-Stathaki and Proudfoot, 2014) . This may contribute to the increased phospho-H2AX staining we observe in monocytes by inducing DNA damage through R-loop formation. Further studies are needed to address this. In addition, the identification of genes involved in ribosome function and translational processes are an interesting consequence of mutant U2AF1 expression, because perturbations in the ribosome have been linked to MDS (Barlow et al., 2010; Ebert et al., 2008; Pellagatti et al., 2008) . If other spliceosome gene mutations (e.g., SRSF2, SF3B1) perturb either of these two pathways, it would suggest a unifying mechanism of action for all these mutations. Ultimately, examination of dysregulated splicing caused by other spliceosome gene mutations and comparison with these findings may help clarify which gene pathways are important.
By performing all of our experiments in a cell-autonomous manner using a transplantation model, transgenic donor bone marrow cells necessarily undergo the stress of repopulating the hematopoietic system in the irradiated microenvironment of recipient mice. However, phenotypes observed in the transplanted mice were also seen in non-transplanted transgenic mice, including bone marrow progenitor expansion and monocyte apoptosis (data not shown). While the transgenic model we describe here could be used to test the dependency of tumors on mutant U2AF1 expression (by removing doxycycline once tumors develop), the overexpression of U2AF1(S34F) or U2AF1(WT) transgene, albeit low, is expected to result in non-stoichiometric levels of U2AF1 relative to other splicing factors. However, no detectable phenotypes were observed in U2AF1(WT)-expressing transgenic mice compared to rtTA only controls. Additional models of U2AF1 mutations (e.g., knockin of S34F at the endogenous U2af1 locus and mice with other U2AF1 mutations) will be important to further characterize the effect of U2AF1 mutations in vivo.
Although this study improves our understanding of mutant U2AF1 biology, our ultimate goal is to improve treatment of patients with U2AF1 mutations. The pervasive nature of spliceosome gene mutations in MDS highlights the need to understand and develop effective therapeutic approaches, perhaps by using splicing modulator drugs. This U2AF1 mouse model may be a useful pre-clinical tool to test potential therapies in a variety of cancers with U2AF1 mutations.
EXPERIMENTAL PROCEDURES
Generation of Doxycycline-Inducible U2AF1(S34F) and U2AF1(WT) Transgenic Mice cDNAs that code for human U2AF1(S34F) and U2AF1(WT) were cloned from an MDS patient bone marrow sample (UPN 571656) by RT-PCR using Superscript III kit (Invitrogen) and introduced individually into the pBS31 0 vector (Beard et al.,
2006) using EcoRI restriction sites. U2AF1(S34F) and (WT) cDNA sequences differed only in the one nucleotide that produced the S34F amino acid conversion. U2AF1(S34F)-pBS31 0 and U2AF1(WT)-pBS31 0 plasmids were introduced into KH2 ES cells by the FLP/FRT system (Beard et al., 2006) to produce U2AF1(S34F) and U2AF1(WT)-expressing ES cell lines. ES cell clones were selected by hygromycin, and integration of U2AF1 (S34F) or (WT)-pBS31 0 was confirmed using PCR and Southern blot approaches. Integration at the 5 0 end was detected using standard Southern blotting techniques as described (Beard et al., 2006) . PCR screening of ES cells and genotyping of mice were performed with the primers described (see Supplemental Experimental Procedures). KH2 ES cells are (C57BL/6 3 129S4Sv/Jae)F1-derived V6.5 embryonic stem (ES) cells (Beard et al., 2006) ; therefore, transgenic mouse colonies were maintained by breeding heterozygous, doubly transgenic mice (U2AF1(S34F)/rtTA and U2AF1(WT)/rtTA) to (C57BL/6 3 129S4Sv/Jae)F1 mice. Doxycycline was administered via doxycycline-containing rodent chow (Pico 5053 base, TestDiet) or via doxycycline in water (in UV light-protected red water bottles, changed every 2 days). All mouse procedures were performed according to protocols approved by the Washington University Animal Studies Committee.
RT-PCR and Pyrosequencing
Following doxycycline induction of transgene expression in vivo, bone marrow cells were harvested from the leg bones. RNA was isolated from bone marrow cell pellets using the RNeasy kit (QIAGEN) followed by DNA removal with Turbo DNA-free kit (Ambion). Reverse transcription PCR was then performed using the Superscript III RT-PCR kit (Invitrogen). PCR for U2AF1 and U2af1 to detect exogenous human transgene and endogenous mouse transcripts expressed in transgenic cells, respectively, was performed, and pyrosequencing for single nucleotide polymorphisms that differ between mouse and human cDNAs was performed on PCR products (primer sequences are listed in the Supplemental Experimental Procedures).
Murine Bone Marrow Transplant and Competitive Repopulation Assays
To generate mice for each experiment, 1 3 10 6 transgenic mouse donor bone marrow cells from two to three mice pooled (CD45.2) were transplanted into at least five lethally irradiated (1,100 rads) wild-type recipient mice (C57BL/6 3 129S4Sv/Jae)F1 (CD45.1/CD45.2) per genotype. Donor mice were between 8 and 12 weeks of age, and recipient mice ranged from 6 to 12 weeks of age; donor and recipient mice were sex-matched. Competitive repopulation assays were performed by mixing transgenic donor ''test'' mouse bone marrow cells (CD45.2) from two to three mice in equal proportions with (C57BL/6 3 129S4Sv/Jae)F1 (CD45.1/CD45.2) donor ''competitor'' mouse bone marrow cells from two to three mice, and then transplanted into (C57BL/6 3 129S4Sv/Jae)F1 (CD45.1/CD45.2) recipient mice. Transgene induction was started R6 weeks after transplantation.
Mouse Hematopoietic Progenitor Assay
Methylcellulose progenitor colony forming assays (CFU-C) were performed using Methocult GF M3434 (Stem Cell Technologies). Bone marrow and spleen cells were obtained from transplanted mice following doxycycline induction of transgene expression. Red blood cells were lysed prior to plating of 10,000 bone marrow cells or 100,000 spleen cells per 1.3 ml media; each sample was evaluated in duplicate. Progenitor colonies (defined as R40 cells/colony) were counted following 7 days culture at 37 C with 5% CO 2 .
Flow Cytometry
Flow cytometry of donor-derived mature cell lineage distribution was performed on bone marrow, peripheral blood, and spleen using the cell surface receptors: CD45.1, CD45.2, CD115, Gr-1, B220, and CD3e (antibodies and procedures described in the Supplemental Experimental Procedures). Apoptosis was evaluated by flow cytometry for Annexin V (APC, BD Biosciences) and intracellular Phospho-H2AX (FITC, JBW301, EMD Millipore) using the BD Cytofix/Cytoperm kit (BD Biosciences) following the manufacturer's recommendations. Donor-derived hematopoietic progenitor and stem cell flow cytometry was performed on bone marrow and spleen using the following cell surface markers (antibodies described in the Supplemental Experimental Procedures): CD45.1, CD45.2, mature lineage (Gr-1, Cd3e, B220, Ter119, and CD41), c-Kit, Sca-1, CD34, Fcg, CD150, CD48, and Flk2. All flow cytometry was performed using FACScan or Gallios cytometers (BD Biosciences) and analyzed using FlowJo software (FlowJo). Progenitor cells were isolated for RNA-seq using an iCyt Synergy flow sorter (Sony).
RNA Sequencing of Common Myeloid Progenitors
Donor-derived common myeloid progenitors (CMPs; lin -, c-Kit + , Sca-1
+ , Fcg À ) cells were sorted from pooled bone marrow of five to seven U2AF1(S34F)/rtTA-or U2AF1(WT)/rtTA-transplanted mice. Cells were sorted into DMEM media, and RNA was prepared from cell pellets using a miRNeasy kit (QIAGEN). Genomic DNA was removed by Turbo DNA-free kit (Ambion). Ribosomal RNA was depleted (Ribozero, Epicenter), followed by cDNA preparation and TruSeq stranded Illumina library production; 2 3 100 bp paired-end sequencing was performed on the HiSeq2000 platform (Illumina).
RNA-Seq Analysis
Reads were aligned to the mouse mm9 reference genome using TopHat (version 2.0.8) (Kim et al., 2013) . All subsequent analyses were performed in R (Gentleman et al., 2004) . Differential gene expression was determined using DESeq2 (version 1.6.1) (Anders and Huber, 2010) , which applies a negative binomial model to counts of reads mapped to genes. Gene models were provided by Ensembl version 67 (Flicek et al., 2013) . Differential junction expression was determined using DEXSeq (version 1.12.1) (Anders et al., 2012) , which applies a negative binomial model to (novel or Ensembl-annotated) junction-spanning read counts while controlling for potential changes in overall gene expression between conditions. Gene enrichment analysis was performed using GOseq (version 1.18.0) (Young et al., 2010) , which accounts for gene-length induced biases. Regions spanning junctions were downloaded from the UCSC Genome Browser (Kent et al., 2002) using BSgenome (version 1.34.0), and their sequence logos were created using seqLogo (1.32.1). Principal component analysis was performed using prcomp, with normalization performed by ggbiplot (version 0.55). Additional bioinformatic analysis of RNA-seq data, including splicing ratio calculation, is described in the Supplemental Experimental Procedures.
RT-PCR and Gel Electrophoresis for Validation of Discovered Altered Junctions
RNA extraction from MDS patient samples, cDNA preparation, and RT-PCR followed by gel electrophoresis were carried out as described elsewhere (Okeyo-Owuor et al., 2014). Briefly, total RNA was treated with DNase using the Turbo DNA-free kit (Ambion), and cDNA was generated using the Superscript III reverse transcriptase kit (Invitrogen). PCR products were electrophoresed in TBE-polyacrylamide gels and stained with ethidium bromide for imaging. Densitometry was performed using ImageJ. PCR primers are described in the Supplemental Experimental Procedures.
All patients provided written consent on a protocol approved by the Washington University Human Studies Committee.
Statistical Analyses
Statistical analysis and generation of graphical presentations of data were performed using analysis functions in GraphPad Prism 6 and as described in the Supplemental Experimental Procedures for RNA-seq analysis.
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